Danaher
DHR | NYSE
$230.15
-$2.87 (-1.23%)
At close: Nov 16, 2026, 4:00 PM ET
$229.91
-$0.24 (-0.10%)
After-hours:
Nov 16, 2026, 6:08 PM ET
Danaher Company Profile
Company profile explainedCompany Profile
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.
Key Executives
| Name | Position |
|---|---|
| Christopher Paul Riley | Executive Vice President of Biotechnology Group & Chief Executive Officer of Cytiva |
| Julie Sawyer Montgomery | President, Chief Executive Officer & Director |
| Jonathan Leiken | Senior VP & Chief Legal Officer |
| Matthew E. Gugino | Chief Financial Officer & Executive Vice President |
| Christopher Bouda | Vice President & Chief Accounting Officer |
| Frank T. McFaden | Vice President and Treasurer |
| Georgeann F. Couchara | Senior Vice President of Human Resources |
| Gregory Milosevich | Executive Vice President of Life Sciences Business |
| James F. O'Reilly | Senior Vice President, Deputy General Counsel, Secretary & Chief Sustainability Officer |
| Jose-Carlos Gutierrez-Ramos | Senior Vice President & Chief Science Officer |
| Matthew R. McGrew | Executive Vice President |
| Mitchell Rales | Co-Founder & Director |
| Rachel Marie Vatnsdal Olson | Vice President of Investor Relations |
| Rainer Blair | Senior Advisor |
| Steven Rales | Co-Founder & Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 4 | Filing |
| Oct 29, 2026 | 4 | Filing |
| Oct 21, 2026 | 8-K | Current Report |
| Oct 21, 2026 | 10-Q | Quarterly Report |
| Oct 16, 2026 | 3 | Filing |
| Oct 16, 2026 | 3 | Filing |
| Oct 14, 2026 | 4 | Filing |
| Oct 14, 2026 | 4 | Filing |
| Oct 13, 2026 | 8-K | Current Report |
| Oct 02, 2026 | 3 | Filing |
Danaher
| Country | United States |
| IPO Date | Dec 29, 1978 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 59,000 |
| CEO | Julie Sawyer Montgomery |
Contact Details
2200 Pennsylvania Avenue, NW Washington,
DC 20037-1701 United States
Stock Details
| Ticker Symbol | DHR |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000313616 |
| CUSIP Number | 235851102 |
| ISIN Number | US2358511028 |
| SIC Code | 3823 |
Recent News
- 7 days ago / marketbeat.comDanaher CEO Sees Faster Growth Ahead, With AI and Acquisitions in Focus
- 8 days ago / seekingalpha.comDanaher Corporation (DHR) Presents at 2026 UBS Global Healthcare Conference Transcript
- 14 days ago / prnewswire.comDanaher to Present at UBS Global and Jefferies Global Healthcare Conferences
- 21 days ago / zacks.comDanaher (DHR) Upgraded to Buy: Here's Why
- 26 days ago / zacks.comLH vs. DHR: Which Stock Is the Better Value Option?
- 26 days ago / seekingalpha.comDanaher Q3 Recap: Decent Results, Still A Hold
- 26 days ago / fool.comWhy Danaher Stock Bounced Higher Today
- 26 days ago / seekingalpha.comDanaher Corporation (DHR) Q3 2026 Earnings Call Transcript
- 26 days ago / fool.comDanaher: 3 Key Takeaways for Long-Term Investors
- 27 days ago / seekingalpha.comDanaher Q3 Review: Interested To See What The New Management Will Bring
Add to Watchlist
Select watchlists to add or remove DHR